Clinical Trial

A Study of VG712 in Patients With Mycosis Fungoides

Study acronym: CurbMF
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
VG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogamulizumab in subjects with relapsed or refractory mycosis fungoides (MF) who have failed 2 or more prior systemic therapies. The study has two parts: a lead-in dosing part (BOIN design, up to 24 subjects) to determine RP2D, followed by a randomized part (approximately 322 subjects, 1:1 VG712 vs. mogamulizumab). Sponsor: Virogen Biotechnology Inc.
Trial Details
NCT Number NCT07529405
Lead Sponsor Virogen Biotechnology Inc.
Collaborators: H. Lee Moffitt Cancer Center and Research Institute
Conditions Mycosis Fungoides
Enrollment 386 participants
Start Date 2026-07-30
Primary Completion 2030-12-30 (estimated)
Study Completion 2032-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-14